Key facts
- This page summarizes Goran Ando's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2023, 09:19.
Goran Ando - 20 Jun 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- Director
- Issuer ticker
- EYPT
- Reported as of
- 20 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2023, 09:19:25 UTC
- Prior SEC filing
- 13 Feb 2023
- Next SEC filing
- 09 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Goran Ando filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 22 Jun 2023.
Change
- Previous filing in this sequence was filed on 13 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +27,100
- Change %
- Price
- $0.000000
- Shares after
- 27,100
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,100
- Exercise price
- $3.26
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,500
- Change %
- Price
- $0.000000
- Shares after
- 13,500
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,500
- Exercise price
- $3.50
* marks a reported price that did not pass the local price check.